Physical Stability and Viscoelastic Properties of Co-Amorphous Ezetimibe/Simvastatin System by Knapik-Kowalczuk, Justyna et al.
  
 
 
 
 
 
 
 
 
 
 
 
Title: Physical Stability and Viscoelastic Properties of Co-Amorphous 
Ezetimibe/Simvastatin System 
 
Author: Justyna Knapik-Kowalczuk, Krzysztof Chmiel, Karolina Jurkiewicz, Natália T. 
Correia, Wiesław Sawicki, Marian Paluch 
 
Citation style: Knapik-Kowalczuk Justyna, Chmiel Krzysztof, Jurkiewicz Karolina, 
Correia Natália T., Sawicki Wiesław, Paluch Marian. (2019). Physical Stability and 
Viscoelastic Properties of Co-Amorphous Ezetimibe/Simvastatin System. 
“Pharmaceuticals” (Vol. 12, iss. 1 (2019), Art. No. 40 ), doi 10.3390/ph12010040 
 
pharmaceuticals
Article
Physical Stability and Viscoelastic Properties of
Co-Amorphous Ezetimibe/Simvastatin System
Justyna Knapik-Kowalczuk 1,* , Krzysztof Chmiel 1 , Karolina Jurkiewicz 1 ,
Natália T. Correia 2, Wiesław Sawicki 3 and Marian Paluch 1
1 Institute of Physics, University of Silesia, SMCEBI, 75 Pułku Piechoty 1a, 41-500 Chorzów, Poland;
krzysztof.chmiel@smcebi.edu.pl (K.C.); karolina.jurkiewicz@us.edu.pl (K.J.);
marian.paluch@us.edu.pl (M.P.)
2 Univ Lille, CNRS, UMR 8207, UMET, Unité Matériaux et Transformations, F59000 Villeneuve d’Ascq, France;
natalia.correia@univ-lille.fr
3 Department of Physical Chemistry, Medical University of Gdansk, 84-416 Gdansk, Poland;
wsawicki@gumed.edu.pl
* Correspondence: justyna.knapik-kowalczuk@us.edu.pl; Tel.: +48-32-3497629
Received: 5 March 2019; Accepted: 16 March 2019; Published: 19 March 2019


Abstract: The purpose of this paper is to examine the physical stability as well as viscoelastic
properties of the binary amorphous ezetimibe–simvastatin system. According to our knowledge,
this is the first time that such an amorphous composition is prepared and investigated. The tendency
toward re-crystallization of the amorphous ezetimibe–simvastatin system, at both standard storage
and elevated temperature conditions, have been studied by means of X-ray diffraction (XRD).
Our investigations have revealed that simvastatin remarkably improves the physical stability of
ezetimibe, despite the fact that it works as a plasticizer. Pure amorphous ezetimibe, when stored
at room temperature, begins to re-crystallize after 14 days after amorphization. On the other
hand, the ezetimibe-simvastatin binary mixture (at the same storage conditions) is physically
stable for at least 1 year. However, the devitrification of the binary amorphous composition was
observed at elevated temperature conditions (T = 373 K). Therefore, we used a third compound to
hinder the re-crystallization. Finally, both the physical stability as well as viscoelastic properties
of the ternary systems containing different concentrations of the latter component have been
thoroughly investigated.
Keywords: ezetimibe; simvastatin; co-amorphous; melt viscosity; solubility enhancement
1. Introduction
Cardiovascular diseases (CVDs) are currently the leading cause of death worldwide for both
men and women [1,2]. Based on data from the Centers for Disease Control and Prevention
(CDC), about 610,000 people in the United States die each year from these diseases. That is
roughly the entire population of Washington, D.C., Vermont, or Wyoming. The cornerstone in
the prevention of CVDs is lowering high blood cholesterol level [3]. Currently, the first-choice
medications for reducing the low-density lipoprotein cholesterol (LDL-C) are statins. They act
by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, thereby blocking
cholesterol synthesis.
Among all statins, atorvastatin and simvastatin are considered as the most potent [4,5].
This explains why they can be found on the list of TOP 5 most prescribed drugs [6]. It has to be pointed
out that an increase in statins dose offers unfortunately limited LDL-C lowering effect (saturation
effect) while at the same time it creates an increased incidence of side effects. Thus, novel active
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pharmaceutical ingredients (APIs) that might reduce LDL-C levels when co-administered with a statin
are of great interest. Ezetimibe is one of such compounds, i.e., a lipid-lowering agent of a new type.
In contrast to statins, which suppress the cholesterol synthesis, ezetimibe inhibits intestinal and biliary
cholesterol absorption by selectively blocking the Niemann–Pick C1- like 1 (NPC1L1) protein. It has
been proven that co-administration of this API with simvastatin is much more effective in reducing
mean plasma concentrations of LDL-C than ezetimibe, simvastatin, and also other statins alone [7,8].
As H. E. Bays et al. indicated, the similar reduction in plasma LDL-C level can be achieved with
the co-administration of ezetimibe 10 mg plus simvastatin 10 mg as with simvastatin 80 mg alone.
In addition, the fixed-dose combination therapy of ezetimibe and simvastatin is well-tolerated by
patients [9]. The efficacy and safety of the combined use of both aforementioned APIs have resulted
in the appearance of such a combo-product on the market. It is available for oral use as tablets
containing 10 mg of ezetimibe and 10, 20, 40, or 80 mg of simvastatin. It is worth mentioning that
the commercial forms of ezetimibe and simvastatin exhibit low oral bioavailability, attributed to its
poor water solubility. Ezetimibe, which has water solubility is equal to 8.46 ng/L, is characterized by
a bioavailability of 35% [10,11]. Simvastatin’s solubility and bioavailability are equal to 1.45 mg/L
and 5%, respectively [12]. Since the permeability of both these drugs is high, they are classified to the
second class of the Biopharmaceutics Classification System (BCS).
There are several methods that can be employed to increase the solubility and consequently also
the bioavailability of APIs from BCS class II [13–15]. One of them is based on the preparation of the
amorphous form of a chosen compound [16–20]. In the literature, one can find a lot of examples
indicating that amorphization remarkably improves the water solubility and bioavailability of poorly
soluble drugs [21–25]. It has to be noted that amorphous APIs have unfortunately one disadvantage,
which blocks their widespread use [26–30]. Mainly, these APIs are physically unstable. It means that
during the time of storage or manufacturing they tend to revert back to their crystalline form [31–35].
In this paper, the binary amorphous composition of ezetimibe and simvastatin in the weight
ratio of 1:1 and ternary amorphous compositions containing ezetimibe 1:1 simvastatin and 5, 20, 40
and 60 wt. % of co-polymer Kollidon VA64 were prepared and thoroughly investigated. Thermal
properties of both the pure components and the obtained systems were investigated by means of
differential scanning calorimetry (DSC). Because the main limitation of widespread use of amorphous
pharmaceuticals is physical instability, we thoroughly examined the tendency toward re-crystallization
of the investigated system at both standard storage and elevated temperature conditions. The physical
stability studies of ezetimibe–simvastatin system were performed by means of X-ray diffraction
technique (XRD). Finally, the oscillatory shear rheology was performed to measure the viscoelastic
properties of all investigated binary and ternary systems. Based on the obtained rheological data,
we plotted the temperature dependences of complex viscosity (η*(T)) of all investigated systems,
which can be used for quick determination of the appropriate concentration, temperature, and viscosity
for the chosen production method of the ezetimibe–simvastatin system.
2. Results and Discussion
2.1. Thermal Properties of Ezetimibe, Simvastatin And Its Binary System
Figure 1 shows the DSC thermograms obtained during heating of the crystalline ezetimibe
(EZB), crystalline simvastatin (SVT), and their physical mixture (EZB/SVT). As can be seen, the DSC
traces of pure components reveal only one endothermic peak corresponding to the samples melting.
The melting onset of EZB is equal to 436 K, while SVT’s Tm = 412 K. Both these values are in good
agreement with the literature data [36,37]. For the physical mixture of EZB/SVT, two thermal effects
are observed on the DSC heating curve. The first with the onset at 391 K is related to solidus (eutectic)
temperature. The second thermal event with the maximum of the peak at a temperature equal to 406 K
and a characteristic tail shape corresponds to the liquidus.
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Figure 1. Differential scanning calorimetry (DSC) thermograms of the pure crystalline ezetimibe (EZB; 
blue line), pure crystalline simvastatin (SVT; red line), and EZB/SVT physical mixture (green line) 
obtained during heating at 10 K/min. 
It is worth emphasizing that the observed decrease in the melting points of both EZB and SVT 
after mixing these two components might be beneficial from the production of the amorphous APIs 
point of view. Currently, for the manufacturing of amorphous pharmaceuticals, the hot melt 
extrusion (HME) method is increasingly employed. During this production process, the crystalline 
API or a drug-polymer composition containing crystalline API is exposed to an elevated temperature 
in order to melt the system. The lower the extrusion temperature, the safer production process, due 
to the decreased probability that the sample will undergo thermal decomposition. 
Figure 2 presents the second heating run of EZB, SVT, and EZB/SVT, which were performed 
immediately after melting and quenching the samples in DSC with a rate equal to 10 K/min. As can 
be seen, the DSC thermograms of freshly melt-quenched samples reveal only one thermal event with 
a characteristic step-like behavior corresponding to the glass transition. The Tg midpoints of EZB, 
SVT, and EZB/SVT are equal to 337 K, 305 K, and 323 K, respectively.  
 
Figure 2. DSC thermograms of quench cooled pure EZB (blue line), pure SVT (red line), and EZB/SVT 
composition (green line). 
Recently, Martinez-Jimenez C. et al. showed that neat amorphous SVT reveals no tendency 
toward re-crystallization for at least one year when stored at room temperature conditions [38]. 
Amorphous EZB, however, quickly reverts to its crystalline form when stored at similar conditions. 
Figure 1. Differential scanning calorimetry (DSC) thermograms of the pure crystalline ezetimibe (EZB;
blue line), pure crystalline simvastatin (SVT; red line), and EZB/SVT physical mixture (green line)
obtained during heating at 10 K/min.
It is worth emphasizing that the observed decrease in the melting points of both EZB and SVT
after mixing these two components might be beneficial from the production of the amorphous APIs
point of view. Currently, for the manufacturing of amorphous pharmaceuticals, the hot melt extrusion
(HME) method is increasingly employed. During this production process, the crystalline API or
a drug-polymer composition containing crystalline API is exposed to an elevated temperature in order
to melt the system. The lower the extrusion temperature, the safer production process, due to the
decreased probability that the sample will undergo thermal decomposition.
Figure 2 presents the second heating run of EZB, SVT, and EZB/SVT, which were performed
immediately after melting and quenching the samples in DSC with a rate equal to 10 K/min. As can
be seen, the DSC thermograms of freshly melt-quenched samples reveal only one thermal event with
a characteristic step-like behavior corresponding to the glass transition. The Tg midpoints of EZB, SVT,
and EZB/SVT are equal to 337 K, 305 K, and 323 K, respectively.
Figure 2. DSC thermograms of quench cooled pure EZB (blue line), pure SVT (red line), and EZB/SVT
composition (green line).
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Recently, Martinez-Jimenez C. et al. showed that neat amorphous SVT reveals no tendency toward
re-crystallization for at least one year when stored at room temperature conditions [38]. Amorphous
EZB, however, quickly reverts to its crystalline form when stored at similar conditions. The first
sign of re-crystallization of amorphous EZB was detected after only 14 days from vitrification by the
melt-quench method [37]. In light of these facts, the physical stability improvement of EZB is needed.
By far, the most common approach to suppress the re-crystallization tendency of amorphous APIs is
to slow down its molecular mobility (i.e., increase their Tg). This is because the molecular dynamic
is believed to be a key factor governing the physical stability of amorphous materials. In EZB/SVT
case the opposite situation is observed—mainly the molecular mobility of physically-unstable EZB
accelerates after the incorporation of SVT. Consequently, one would speculate that SVT might decrease
the physical stability of an amorphous EZB.
2.2. Physical Stability Studies of the Amorphous Ezb/Svt System Stored at Both Supercooled Liquid and
Glassy State
In order to assess how the SVT changes the physical stability of the amorphous form of EZB,
the amorphous EZB/SVT mixture was subjected into two independent XRD experiments. The idea of
the first one was to check the mixture’s physical stability at standard storage conditions, i.e., at 298 K
and RH = 60%. During the second experiment, the sample was stored at elevated temperature
conditions (T = 373 K). The representative XRD patterns obtained during these experiments are
presented, together with the diffractograms of the crystalline EZB, SVT, and EZB/SVT, in Figure 3a–c.
It is worth mentioning that the XRD patterns of pure crystalline APIs are in agreement with previous
results [38,39]. The samples measured immediately after quenching, as expected, were fully amorphous.
The -sharp Bragg’s peaks are not visible on their XRD patterns.
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and then once a month until 1 year. As can be clearly seen even after 1 year, the examined EZB/SVT 
system did not reveal any sign of re-crystallization. Comparing this result with the previously 
published by Knapik et al., data for pure EZB, one can conclude that SVT impressively stabilizes EZB. 
It should be emphasized that herein the improvement of physical stability was achieved despite 
acceleration the EZB’s molecular mobility. The similar situation was previously observed only in two 
cases: Nifedipine + nimodipine and simvastatin + nifedipine [39,40]. Such a stabilization effect was 
explained by the existence of some specific interactions between both drugs. Accordingly, one can 
expect that, in the EZB/SVT system, the source of the observed stabilization is analogous to the 
aforementioned cases. 
Figure 3. XR patterns of (a) crystalline syste s stored at 298 (red line pure S T; blue line pure
EZB; green line EZB/SVT physical mixture), (b) amorphous EZB/SVT system stored at 298 K,
(c) amorphous EZB/SVT system stored at 373 K.
The amorphous form of EZB/SVT composition stored at standard storage conditions was
measured by means of XRD at the beginning once daily for a week, later once a week for a month,
and then once a month until 1 year. As can be clearly seen even after 1 year, the examined EZB/SVT
system did not reveal any sign of re-crystallization. Comparing this result with the previously
published by Knapik et al., data for pure EZB, one can conclude that SVT impressively stabilizes
EZB. It should be emphasized that herein the improvement of physical stability was achieved despite
acceleration the EZB’s molecular mobility. The similar situation was previously observed only in two
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cases: Nifedipine + nimodipine and simvastatin + nifedipine [39,40]. Such a stabilization effect was
explained by the existence of some specific interactions between both drugs. Accordingly, one can
expect that, in the EZB/SVT system, the source of the observed stabilization is analogous to the
aforementioned cases.
During the second XRD experiment, in which the sample was exposed to the elevated temperature
conditions (T = 373 K), the XRD patterns were collected every 30 min for 30 h. The representative
diffraction patterns are presented in Figure 3c. At this temperature, the first appearance of sharp
Bragg’s peaks was noticed after only 210 min. This result indicates that even if the amorphous
EZB/SVT system reveals high physical stability when stored below the glass transition temperature,
it tends to re-crystallize at a supercooled liquid state. Such a situation is acceptable if for sample
manufacturing one would choose a method which does not require sample heating (ex. Spray Drying).
It, however, might not be sufficient in cases of production methods involving thermal processing,
such as hot melt extrusion or 3D printing.
2.3. Impact of KVA 64 Polymer on the Thermal Properties as Well as Physical Stability of the EZB/SVT System
Kollidon VA64 (KVA 64) is a vinylpyrrolidone—a vinyl acetate copolymer. It is amorphous in
nature, with a glass transition temperature equal to 378 K and degradation temperature ~500 K [40].
This polymer is well soluble in water and has good processability, and therefore it is commonly used as
an excipient for manufacturing of amorphous pharmaceutical products using either solvent (ex. Spray
Drying (SD)) or melting (ex. Hot Melt Extrusion (HME)) methods. In such formulations, usually,
KVA64 plays a dual role. On the one hand it increases the dissolution rate of the APIs, and on the other
hand, it well stabilizes them.
In this section, the impact of KVA64 on the thermal properties and physical stability of
a co-amorphous composition containing EZB and SVT is described. Figure 4a presents DSC
thermograms of the EZB/SVT physical mixture, neat (as received) KVA 64 polymer, as well as four
ternary physical mixtures of EZB, SVT, and KVA in the concentrations: (i) EZB/SVT + 5wt. % KVA,
(ii) EZB/SVT + 20wt. % KVA, (iii) EZB/SVT + 40wt. % KVA and (iv) EZB/SVT + 60wt. % KVA. As it
has been shown in the first section, the DSC curve of the EZB/SVT crystalline system reveals two
thermal events. The first one associated with the eutectic, and the second one reflecting the liquidus.
DSC thermogram of the first run of KVA64 reveals only one endothermic event visible in the vicinity of
320–380 K that corresponds to water evaporation. This broad endothermic peak covers the polymer’s
glass transition that can be easily noticed at a second DSC heating run (see the black curve in Figure 4b),
or (ii) first DSC heating run obtained after sample heating at 373 K for 15 min (data not shown). In the
DSC traces of ternary systems (i) and (ii), three thermal endotherms might be noted. First, a very
broad thermal event reflecting water evaporation can be found in the vicinity of 320–350 K. A second,
with an onset in the neighborhood of 390 K, is connected with the eutectic transition. The third one is
visible around 410 K and possesses a characteristic tail shape associated with the liquids phase. On the
thermograms of systems (iii) and (iv) the latter endothermic peak becomes invisible, indicating that
the ternary eutectic EZB/SVT/KVA was obtained.
Melts of the examined ternary systems have been quenched in DSC with a rate equal to 10 K/min
to obtain the amorphous compositions. The glassy samples were subsequently reheated up to T = 440 K
while obtained thermograms and are presented in Figure 4b. As can be seen, the amorphous mixtures
containing EZB, SVT, and KVA are characterized by a single glass transition event which shifts toward
a higher temperature with increasing co-polymer content. The presence of a single Tg in binary or
ternary compositions usually indicates that these systems are homogenous [41]. If mixtures are not
or are only partially miscible, the DSC trace of an amorphous system should reveal multiple Tgs.
These can be due to the presence of various drug or polymer rich domains [29]. The values obtained
by means of DSC technique, Te, Tl, and Tg, for all examined samples are presented in Figure 4 and are
collected in Table 1.
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EZB/SVT + 40wt. % KVA (yellow lines), EZB/SVT + 60wt. % KVA (orange lines) and KVA (black lines).
Mixing of the multi-components can either be ideal and non-ideal [41–43]. The deviation from the
ideal mixing in amorphous binary, ternary, or quaternary systems might be examined by comparing
the experimental glass transition temperature with the Tg predicted from the Couchman-Karasz (CK)
equation given as follows [44,45]:
Tg =
∑∆CpixiTgi
∑∆Cpixi
(1)
where xi is a mass fraction of component i, ∆Cpi refers to the change in heat capacity of component i
betw en its liquid-like and glassy states, and Tgi d notes a glass transition temperature of co ponent i.
The similarity in predicted and experime tally termined Tg values strongly suggests ideal mixi g,
whil positive and negat ve eviation indicates that th ixing is non-ideal [41]. As can be seen in
Figure 5 and Table 1, the predicted and experimentally obtained Tg values are i very good agreement
indicating that there is good molecular miscibility between all three components, as well as an absence
of the intermolecular interaction between them.
Table 1. Comparison of Te, Tl, Tg exp, and Tg pred values of pure KVA, the binary mixture of EZB/SVT,
as well as the ternary system of EZB/SVT/KVA containing 5, 20, 40 and 60 wt. % of KVA.
System Te [K] Tl [K] Tg exp [K] Tg pred [K]
EZB/SVT 391 406 323 323
EZB/SVT + 5wt.% KVA 390 406 324 324
EZB/SVT + 20wt.% KVA 389 401 332 332
EZB/SVT + 40wt.% KVA 388 - 345 342
EZB/SVT + 60wt.% KVA 388 - 355 353
KVA - - 378 -
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To determine how the polymeric additive influx effects the physical stability of EZB/SVT system,
the ternary amorphous system containing the lowest amount of the co-polymer has been investigated
by means of XRD. The short-term XRD experiment of EZB/SVT + 5wt. % KVA was performed at
elevated temperature conditions (T = 373 K). During these studies, the mixture’s XRD patterns were
collected every 30 min for 60 h. The obtained results are presented in Figure 6. The XRD patterns of both
freshly vitrified as well as stored at elevated temperature conditions for 60 h EZB/SVT + 5wt. % KVA
mixture reveal a lack of Bragg’s peaks. This indicates that the sample remained amorphous throughout
the duration of the experiment. Comparing this result with the data presented in Figure 3c, one can
conclude that KVA significantly i proves the physic l stability of the a orphous EZB/SVT system at
elevated temperature conditions (T = 373 K).Pharmaceuticals 2019, 12, x 8 of 15 
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a function of storage time at elevated temperature conditions (T = 373 K).
2.4. The Impact of KVA on the Complex Viscosity of the EZB/SVT System
The experiments presented in the previous section proved that even a very small amount of
KVA (5wt. %) is able to very effectively suppress the tendency toward re-crystallization of EZB/SVT
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composition at elevated temperature conditions. It is worth repeating that the physical stability
improvement of this binary amorphous drug-drug system is needed only if the chosen production
method will involve thermal processing. The best representatives of such methods are hot melt
extrusion (HME) or 3D printing (3DP). This kind of manufacturing processes typically includes three
stages: (i) Heating and softening of a physical mixture containing API and thermoplastic polymer;
(ii) pressurization of molten mass through a die, and (iii) sample solidification, during which the
final dosage form is formulated [46–51]. To obtain the desired shape of a final product, samples
besides high physical stability needs to be characterized by suitable melt viscosity. For example,
the small scale extruder required the sample’s melt viscosity at a range of 800–10,000 Pa·s [52]. Thus,
in this section, the viscosity of EZB/SVT and its mixtures with KVA have been also investigated.
Both the EZB/SVT binary physical mixture as well as the ternary mixtures containing EZB/SVT and
KVA polymer have been placed between the fixtures of rheometer and heated up to 413 K. At this
particular temperature, the samples were melted and then the gap was set. Next, the material’s
complex viscosity was examined in the wide frequency (0.016–15.916 Hz) and temperature (413–353 K)
range. The representative complex viscosity curves as a function of frequency are presented in Figure 7.Pharmaceuticals 2019, 12, x 9 of 15 
 
 
Figure 7. Temperature sweep data showing complex viscosity as a function of frequency of (a) the 
binary amorphous EZB/SVT system, (b) the ternary amorphous system of EZB/SVT + 5wt.% KVA, (c) 
the ternary amorphous system of EZB/SVT + 20wt.% KVA, (d) the ternary amorphous system of 
EZB/SVT + 40wt.% KVA, (e) the ternary amorphous system of EZB/SVT + 60wt.% KVA and f) the neat 
KVA polymer. 
Figure 8 shows the temperature dependences of viscosity values from the plateau region for all 
investigated materials, i.e. pure KVA, the binary amorphous system of EZB/SVT, and four ternary 
amorphous systems containing EZB/SVT and 5, 20, 40, and 60 wt. % of KVA. In order to parameterize 
the temperature dependence of complex viscosity, we employed the Vogel-Fulcher-Tamman (VFT) 
equation that is defined as follows [53–55]: 
𝑙𝑜𝑔ଵ଴ሺ𝑇ሻ = 𝑙𝑜𝑔ଵ଴ஶ +
𝐷𝑇଴
𝑇 − 𝑇଴ (2) 
where T is temperature and η∞, D, T0 are parameters obtained by fitting Equation 2 to experimentally 
measured viscosity data. All fitting parameters are collected in Table 2.  
Table 2. Comparison of the VFT fitting parameters for neat KVA, the binary mixture of EZB/SVT, and 
ternary systems of EZB/SVT/KVA containing 5, 20, 40 and 60wt. % of the polymer. 
System Log10η∞ B = DT0 T0 
EZB/SVT 4.67 ± 0.17 1148.34 ± 60.19 295.12 ± 1.86 
EZB/SVT + 5wt.% KVA −4.55 ± 0.09 1303.53 ± 37.27 290.77 ± 1.22 
EZB/SVT + 20wt.% KVA −6.19 ± 2.67 2411.64 ± 148.98 269.49 ± 3.66 
EZB/SVT + 40wt.% KVA −5.59 ± 0.22 2515.29 ± 126.57 273.42 ± 3.04 
EZB/SVT + 60wt.% KVA −7.15 ± 0.4 3816.61 ± 278.45 253.35 ±5.37 
KVA −4.13 ± 0.83 2981.70 ± 565.27 278.26±13.87 
Based on Figure 8, where the temperature dependencies of |η*| of all investigated materials are 
summarized, it is possible to quickly determine both the KVA polymer content and the temperature 
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binary amorphous EZB/SVT system, (b) the ternary amorphous system of EZB/SVT + 5wt.% KVA,
(c) the ternary amorphous system of EZB/SVT + 20wt.% KVA, (d) the ternary amorphous system of
EZB/SVT + 40wt.% KVA, (e) the ternary amorphous system of EZB/SVT + 60wt.% KVA and f) the
neat KVA polymer.
As can be seen with decreasing the temperature, the samples become more viscous and the
viscosity plateau is less pronounced and shifts toward lower frequencies. In this case, the complex
viscosity is low, i.e., the sample is more elastic at higher frequencies and increases with decreasing
frequency culminating in a consistent viscosity plateau. The lower the polymer content, the less
viscous the sample is at constant T, and the more pronounced is the viscosity plateau on the |η*|(f).
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The shadowed area indicates the generally accepted ‘rule-of-thumb viscosity range’ for small-scale
extrusion [52]. The |η*|(f) marked by the dashed lines refer to the temperatures higher or equal to the
liquidus temperature. As can be seen, EZB/SVT, EZB/SVT + 5wt. % KVA and EZB/SVT + 20wt. % of
KVA possess suitable for small scale extruder viscosity value at the temperatures below the liquidus
temperature. Therefore, extrusion of such products is impossible. Suitable melting viscosity at T equals
or higher than the liquidus temperature can be reached when 40 or higher wt. % of the polymer is
employed (see Figure 7d–f).
Figure 8 shows the temperature dependences of viscosity values from the plateau region for all
investigated materials, i.e., pure KVA, the binary amorphous system of EZB/SVT, and four ternary
amorphous systems containing EZB/SVT and 5, 20, 40, and 60 wt. % of KVA. In order to parameterize
the temperature dependence of complex viscosity, we employed the Vogel-Fulcher-Tamman (VFT)
equation that is defined as follows [53–55]:
log10η(T) = log10η∞ +
DT0
T − T0 (2)
where T is temperature and η∞, D, T0 are parameters obtained by fitting Equation (2) to experimentally
measured viscosity data. All fitting parameters are collected in Table 2.
Table 2. Comparison of the VFT fitting parameters for neat KVA, the binary mixture of EZB/SVT, and
ternary systems of EZB/SVT/KVA containing 5, 20, 40 and 60wt. % of the polymer.
System Log10η∞ B = DT0 T0
EZB/SVT 4.67 ± 0.17 1148.34 ± 60.19 295.12 ± 1.86
EZB/SVT + 5wt.% KVA −4.55 ± 0.09 1303.53 ± 37.27 290.77 ± 1.22
EZB/SVT + 20wt.% KVA −6.19 ± 2.67 2411.64 ± 148.98 269.49 ± 3.66
EZB/SVT + 40wt.% KVA −5.59 ± 0.22 2515.29 ± 126.57 273.42 ± 3.04
EZB/SVT + 60wt.% KVA −7.15 ± 0.4 3816.61 ± 278.45 253.35 ± 5.37
KVA −4.13 ± 0.83 2981.70 ± 565.27 278.26 ± 13.87
Based on Figure 8, where the temperature dependencies of |η*| of all investigated materials are
summarized, it is possible to quickly determine both the KVA polymer content and the temperature
range, which are suitable to produce physically-stable amorphous EZB/SVT system by means of
the melting methods. For example, in the case of small-scale extrusion, where the recommended
material’s viscosity range between 800–10,000 Pa·s, the lowest available concentration is equal to
40wt. %. Choosing this particular concentration of the excipient, the minimum temperature needed for
sample melting is equal to 398 K. It is worth highlighting that for higher polymer concentrations, higher
T conditions should be selected (ex. 60wt% of KVA – T ≥ 403 K). To better visualize it, we marked in
Figure 8 the viscosity area which is appropriate for small scale extrusion and the liquidus temperatures
for each examined concentration. Finally, in the shadowed area one can find suitable for extrusion
EZB/SVT/KVA compositions and temperatures.
According to the experimental results presented above, in order to produce the EZB/SVT system
by means of small-scale extruder, a minimum of 40wt. % of KVA co-polymer should be added.
Such a ternary system should be melted at T ≥ 389 K. To make sure that T = 389 K is indeed high
enough to fully amorphize the sample, as well as to investigate whether such a system will be physically
stable at both standard storage and elevated temperature conditions, we investigated a quenched
from T = 398 K EZB/SVT + 40wt. % KVA sample by means of XRD. The representative XRD patterns
obtained during this experiment are presented in Figure 9. As can be seen, the diffraction pattern of the
freshly prepared sample (quenched from T = 398 K) do not reveal sharp Bragg’s peaks, indicating that
T = 389 K is high enough to fully melt the sample. In the next step of the XRD experiment, the vitrified
sample has been heated up to 373 K and stored for 30 h. After each 30 min, the XRD pattern has been
registered. As data presented in Figure 9 proves, the investigated EZB/SVT/KVA system was for all
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that time fully amorphous. The last stage of the XRD measurement consisted in keeping the cooled
down to T = 298 K ternary composition for a period of 3 months. The sample’s diffraction patterns
were collected one a day for a week, next once a week for a month, and finally once a month for 3
months. Data presented in Figure 9 indicates that the examined ternary system is physically stable for
at least 3 months after amorphization and annealing at T = 373 K for 30 h.
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3. Materials and Methods
3.1. Materials
Ezetimibe drug (EZB) of purity greater than 99% and molecular mass Mw = 409.4 g/mol was
purchased from Polpharma (Starogard Gdan´ski, Poland) and used as received. This pharmaceutical
is described chemically as ((3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-
(4-hydroxyphenyl)azetid in-2-one), with its chemical structure presented in blue inset of Figure 1.
Simvastatin drug (SVT) of purity greater than 98% and molecular mass Mw = 418.6 g/mol was
purchase from ACOFARMA and used as received. This pharmaceutical is described chemically
as Butanoic acid, 2,2-dimethyl-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)
-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, with its chemical structure
presented in the red inset of Figure 1. Kollidon VA64 polymer (KVA) of molecular mass
Mw = 45,000–47,000 g/mol was purchased from BASF SE (Germany) and used as received.
3.2. Preparation of Binary and Ternary Systems
Both binary amorphous mixtures of EZB and SVT, as well as ternary amorphous systems of
EZB/SVT and KVA with different content of the polymer (5, 20, 40, 60wt.% KVA), were prepared by
the quench cooling technique. To obtain the homogenous systems prior to the quenching, the physical
mixtures were obtained by gentle mixing the appropriate number of samples in a mortal for 15–20 min.
3.3. Differential Scanning Calorimetry (DSC)
Thermodynamic properties of EZB, SVT, KVA and their binary and ternary systems were
examined using a Mettler–Toledo DSC 1 STARe System. The measuring device was equipped with
an HSS8 ceramic sensor having 120 thermocouples. The instrument was calibrated for temperature
and enthalpy using indium and zinc standards. Crystallization and melting points were determined
as the onset of the peak, whereas the glass transition temperature as the midpoint of the heat capacity
increment. The samples were measured in an aluminum crucible (40 µL). All measurements were
carried out with a heating rate equal to 10 K/min.
3.4. X-ray Diffraction (XRD)
X-ray diffraction experiments were performed for samples stored at both ambient and
elevated temperature conditions on a Rigaku-Denki D/MAX RAPID II-R diffractometer (Rigaku
Corporation, Tokyo, Japan) with a rotating anode Ag KR tube (λ = 0.5608 Å), an incident beam
(002) graphite monochromator, and an image plate in the Debye−Scherrer geometry. The pixel
size was 100 µm × 100 µm. Measurements were performed on sample-filled and empty capillaries,
to allow subtraction of the background intensity. The beam width at the sample was 0.1 mm.
The two-dimensional diffraction patterns were converted into one-dimensional intensity data versus
the scattering angle.
3.5. Rheological Studies
The viscoelastic properties of neat KVA, the binary system of EZB and SVT, as well as ternary
systems containing EZB1:1SVT + different KVA content (5wt%, 20wt.%, 40wt.% and 60wt.%) were
measured by means of ARES G2 Rheometer. The instrument was equipped with aluminum parallel
plates geometry (diameter = 25 mm). Prior to the oscillation, temperature sweep rheological
experiments the samples were placed between the fixtures of rheometer and heated up to 413 K
(or T = 458 K for neat KVA). At this particular temperature, the examined materials were melted (or
liquefied in the case of neat polymer) and then the gap was set at ~1 mm. Next, the material’s complex
viscosity was examined in the wide temperature range and frequencies from 0.016–15.916 Hz.
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4. Conclusions
In this article, the binary amorphous composition of ezetimibe and simvastatin was investigated by
means of differential scanning calorimetry, X-ray diffraction, and oscillatory shear rheology. We found
that the simple melt-quenching method can be applied to obtain a homogeneous binary system of
these two pharmaceuticals. Thermal analysis of the pure crystalline components, as well as physical
mixture of ezetimibe and simvastatin, indicated that co-administration of these two APIs leads to
melting point depression. The long-term stability studies performed by XRD at standard storage
conditions (i.e., T = 298 K and RH = 60%) have proven that simvastatin, despite the fact that it acts as
a plasticizer, remarkably improves the physical stability of amorphous ezetimibe drugs. Unfortunately,
the stabilization effect is not enough for the case when the sample is planned to be produced at
elevated temperature—at elevated temperature conditions (T = 373 K), the re-crystallization of the
sample was registered. To overcome this problem, the third component, co-polymer Kollidon VA 64,
was proposed as a mixture stabilizer. The physical stability studies performed at elevated temperature
conditions indicated that even a small amount of the polymeric additive (5 wt. %) may significantly
suppress tendency towards the devitrification of the ezetimibe–simvastatin composition. The first
sign of devitrification of the binary amorphous composition noted after 3h and 30 min, while the
ternary system containing 5 wt. % of the polymer was physically stable for at least 60 h (when stored
at T = 373 K).
Finally, the effect of Kollidon VA64 on the viscoelastic properties of the EZB/SVT system in their
ternary amorphous compositions was investigated using oscillatory shear rheology. Plots containing
temperature dependencies of complex viscosity of all examined systems—constructed based on the
rheological data—allowed us to estimate the most suitable, for small scale extrusion, temperature
conditions, as well as the polymer concentrations. In order to obtain suitable melt viscosity of the
ezetimibe–simvastatin composition, at least 40 wt. % of the polymer is needed. For this particular case,
the lowest available temperature is equal to 398 K.
In summary, the binary amorphous ezetimibe–simvastatin system is a very promising candidate
for new formulations intended for combined therapy. Apart from the medical and economic benefits
of using these APIs together in amorphous forms, such a binary composition provides high physical
stability that is essential for further commercial application. For the production of this binary system by
melting methods, such as hot melt extrusion or 3D printing, the addition of Kollidon VA64 is required.
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